“MT-act is a preclinical stage spin-off company, stemming from a CNRS research institute dedicated to cutting-edge biological sciences and understanding of human pathophysiology. We develop class compounds to treat human pathologies that share a common molecular defect; dysfunction of the microtubular network. The company roots on a unique platform technology providing chemical versatility to develop first-in-class drugs that serve multiple development programs. Employing a knowledge-based view, MT-act develops drug candidates to correct microtubule dysfunctions. The choice of the targeted mode of action is highly differentiated.”
Home 
About us 
Offer 
News 
